+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Absence of cervical radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for locally advanced, unresectable, nonmetastatic squamous cell carcinoma of the head and neck



Absence of cervical radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for locally advanced, unresectable, nonmetastatic squamous cell carcinoma of the head and neck



Journal of Cancer Research and Clinical Oncology 127(11): 687-691



Purpose: To evaluate the risk of developing radiation myelitis after a cervical spinal cord dose of 50.6 Gy given via 1.1 Gy b.i.d. fractionation during a prospective, randomised trial of hyperfractionated radiation therapy (HFX RT) to a total dose of 77 Gy given in 70 fractions of 1.1 Gy b.i.d., with and without concurrent low-dose, daily cisplatin (CDDP) for head and neck cancer. Methods: Of 130 patients with locally advanced, unresectable, nonmetastatic squamous cell carcinoma of the head and neck (SCC H&N) who entered a prospective, randomised trial, 101 patients received 50.6 Gy to a portion of their spinal cord and survived >1 year following the beginning of therapy. Forty-five patients were treated with HFX RT alone and fifty-six patients also received CDDP. Results: None of these 101 patients developed cervical radiation myelitis. Therefore, it was not possible to investigate the influence of potentially contributing factors on the occurrence of radiation myelitis, such as interfraction interval, cord length, and administration of concurrent CDDP. Conclusions: Given the increasing number of studies with both altered fractionated regimens and concurrent radio-chemotherapy in SCC H&N, new studies with more patients are needed to gain better insight into the risks of developing cervical radiation myelitis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010112365

Download citation: RISBibTeXText

PMID: 11710599

DOI: 10.1007/s004320100269


Related references

Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 22(17): 3540-3548, 2004

Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. American Journal of Clinical Oncology 32(2): 163-168, 2009

Hyperfractionated accelerated radiation therapy with concurrent interferon alpha and isotretinoin for patients with locally advanced squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology Biology Physics 30(Suppl. 1): 258, 1994

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. Journal of Clinical Oncology 18(7): 1458-1464, 2000

Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma. International Journal of Clinical Oncology 21(6): 1030-1037, 2016

Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiotherapy and Oncology 43(1): 29-37, 1997

High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study. Head and Neck 22(6): 543-549, 2000

Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma. Head and Neck 31(2): 167-174, 2009

Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study. Strahlentherapie und Onkologie 193(9): 733-741, 2017

Induction chemotherapy followed by hyperfractionated radiation therapy in unresectable squamous cell carcinoma of the head and neck Experience with an institutional protocol. EJC Suppl.s 1(5): S43, 2003

Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology 26(15_Suppl): 6006-6006, 2016

Pretreatment prognostic factors of local recurrence-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. American Journal of Clinical Oncology 31(3): 213-218, 2008

Hyperfractionated radiotherapy with or without concurrent low-dose daily cisplatin in locally advanced unresectable squamous cell carcinoma of the head and neck A prospective randomized trial. European Journal of Cancer 35(Suppl. 4): S163, 1999

Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. Journal of Clinical Oncology 11(11): 2136-2142, 1993

Pretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. American Journal of Clinical Oncology 32(5): 483-487, 2009